## HemoCue Hb 201+: Appendix C – Microcuvettes

| **Microcuvettes Hemocue Hb 201+** | | | |
|---|---|---|---|
| Microcuvettes Hb 201+:<br>• Sealed Vial -50 each<br>• Box of individually packaged – 50 each<br>• Package insert.<br>*Note: Microcuvettes are designed to be used with the Hemocue Hb 201+ or Hemocue Hb 201 DM Analyzer exclusively.* |  <br>Sealed Vial – 50 ea |  <br>Box of individually packaged – 50 ea |  <br>View of open microcuvette |
| ***Note: Preferred packaging is the Box of individually wrapped microcuvettes.*** | | | |

### Stock Storage

- Stock supply is at room temperature (15-30$^{o}$C) Laboratory – POCT Room 2J8.
- Document Microcuvette Utilization on Form – located with the stock supply.

### Ward Storage:

- Microcuvettes stored at room temperature with the Hemocue Hb 201+ analyzer.

*Note: Sealed Vial – 50 each – Replace cap immediately.*
*Open container stability is 3 months.*
*Individually packaged – use within 5 minutes of opening package seal.*

### Sample

- 10 uL whole blood. Use fresh capillary blood. (venous or arterial may be used)

### Principle of the Test

- Microcuvette is made of plastic and comprises a body having a cavity with a volume of about 10 uL
- The Microcuvette contains dry reagents deposited uniformly within the cavity.
- Whole blood sample is drawn into the cavity by capillary action and is mixed spontaneously with the reagents. No manual mixing is required.
- Microcuvette is placed into the HemoCue Hb 201+ analyzer and the chemical reaction (Modified azidemethemoglobin reaction), is measured photometrically at endpoint – two wavelengths 570 and 880 nm for turbidity compensation.

### Microcuvette Reagent Composition

- 40 % w/w Sodium Deoxycholate; 18 % w/w Sodium Azide; 20 % w/w Sodium Nitrite; 22 % w/w Nonreactive Ingredients.

### Measuring Range, reproducibility and accuracy.

- Linear to 235 g/L. Confirm results > 235 g/L with laboratory method.
- Results > 256 g/L are reported as “HHH” on the meter display.
- Reproducibility: Level 1 (77 g/L) CV = 0.74 %; Level 2 (154 g/L) CV=0.51%
- Precision: 7 sets data; Range 41 – 210 g/L; Regression Y= 0.981X-1.045; Correlation Coefficient r=0.994-0.999.

| **Test Limitations:** |
|---|
| • Measurement is immediately after the blood is drawn into the microcuvette.<br>• Measurement after 10 minutes of filling the microcuvette will lead to false results.<br>• Air bubbles present in the center of the microcuvette cavity should be discarded. Air bubbles around the edge do not affect the result.<br>• Do not hold the microcuvette by the filling end. Wipe excess specimen from the outer surface of the optical eye. |
| **Interfering Substances** |
| Highest concentration tested is referred to in brackets. Following has not been found to interfere:<br>• Acetaminophen (1324 umol/L); ascorbic acid (170 umol/L); conjugated bilirubin (1365 umol/L); unconjugated bilirubin (324 umol/L); ibuprofen (1939 umol/L); creatinine (2652 umol/L); salicylic acid (3620 umol/L); tetracycline (20 mg/dl); urea (179 mmil/L); uric acid (1190 umol/L); lipaemia (Intralipid 4.6 mmol/L, approx. Triglycerides 13.7 mmol/L). |

## REFERENCES

**HemoCue Hb 201+ Operating Manual. HemoCue AB, Box 1204 SE-262 23 Angelholm, Sweden. info@hemocue.se www.hemocue.com**

**HemoCue Hb 201 Microcuvettes, Package Insert. HemoCue AB, Box 1204 SE-262 23 Angelholm, Sweden. info@hemocue.se www.hemocue.com**

**Eurotrol HemoTrol, Assayed Controls for In Vitro Diagnostic Use, Package Insert. Eurotrol B.V. Postbus 722 6710 BS Ede, The Netherlands office@eurotrol.com www.eurotrol.com**

## REVISION & APPROVAL LOG

| Version | Revision Type | Description of Change | Revision Date | Technical Approval | Medical Approval |
|---|---|---|---|---|---|
| 1.0 | | New document | Jun 2012 | Elvira Kozak | Dr. Cathy Halstead |
| 1.1 | Minor | Document title and number change. Upload to QMS document control | 28 Dec 2016 | | Dr. Benjamin Jung |
| | | | | | |

**Attention: This document is published on the BCCW SharePoint website**

**Revisions made to this document require an update to the corresponding document published on BCCW SharePoint website**